Public Good Pharma develops new low-cost therapies from system-wide cost savings of pharmaceutical payers Our model employs 2 key mechanisms: Interventional Pharmacoeconomic (IVPE) clinical trials generate guaranteed cost savings for payers by comparing in-use, expensive therapies to low-cost, safe and effective alternatives + Pay-For-Success Contracts (PFS) allow payers to incentivize regulatory approval for a low-cost alternative without taking risk. If IVPE trials are successful, PFS contracts guarantee supply.